Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
BAY 87-2243 was dosed to Mice bearing lung carcinoma H460 xenografts via oral gavage at 4 mg/kg once per day
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics
and reduced brain atrophy
CAS Number: 325715-02-4
3-dimethyl-5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1
RK-33 - DDX3 inhibitor. CAS# 1070773-09-9 Catalog No.:M6511-2 BAY 87-2243 was dosed toDDX3 inhibitor, CAS No. 1070773 09 9, RK 33 binds to DDX3 and abrogates its activity. Inhibition of DDX3 by RK 33 caused G1 cell cycle arrest, induced apoptosis, and promoted radiation sensitization in DDX3 overexpressing cells. Overall, inhibition of DDX3 by RK 33 promotes tumor regression, thus providing a compelling argument to develop DDX3 inhibitors for lung cancer therapy. RK 33 radiosensitizes prostate cancer cells by blocking the RNA helicase
US$ 107.00
US$ 129.25
US$ 144.00
US$ 106.50
US$ 308.50
US$ 241.50
US$ 176.50
US$ 107.50
US$ 380.00
US$ 280.50
US$ 175.00
US$ 97.00
US$ 168.00
US$ 156.00